Allergan: FDA Approve Botox For Lower Limb Spasticity Treatment In Adults

(RTTNews) - Allergan plc (AGN) said that the U.S. Food and Drug Administration or FDA has approved Botox, or onabotulinumtoxinA, for the treatment of lower limb spasticity in adult patients to decrease the severity of increased muscle stiffness in ankle and toe muscles.

Allergan noted that Botox is the first and only botulinum toxin product to be approved by the FDA to treat multiple muscle groups of both the upper and lower limbs that may be impacted by spasticity.

Botox was first approved for the treatment of upper limb spasticity (ULS), or increased muscle stiffness in the elbow, wrist and fingers, in adults in March 2010. Additional FDA approval was received in April 2015 to expand the Botox label for the treatment of adults with ULS to include the addition of two thumb muscles.

Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which may interfere with movement, or be associated with discomfort. Affecting about 1 million people in the U.S., spasticity is usually caused by damage to the portion of the brain or spinal cord that controls voluntary movement.